4 Reasons to Consider Investing in Corcept Therapeutics!
The market for Corcept could expand to 1.5 million patients, representing a significant increase from the previous estimate of 20,000 patients.
If the FDA approves the new drug Relacorilant, it would lead to considerable market expansion.
Reading Time: 1 minute
Screening for Cushing's syndrome is becoming increasingly common, and the number of patients receiving appropriate treatment continues to rise. For the year 2025, consensus at Corcept only expects revenue growth of 17% to $801 million after over 40% in 2024. This seems very low to me, as management suggests that the market could expand to 1.5 million patients, which represents a significant increase from the previous estimate of 20,000 patients. A potential FDA approval for Relacorilant would mean considerable market expansion and help achieve...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
